Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Leukemia
•
Hematology
How do you treat recurrent sweet's syndrome in AML?
Related Questions
How would you manage an elderly patient with mild pancytopenia who refuses bone marrow biopsy and whose flow cytometry is suggestive of CMML/MDS?
Would concurrent CRLF2/IgH rearrangement affect your treatment recommendations for an adult patient with Ph+ p190 high risk (Age>35, WBC >30) B-cell ALL that was started on induction therapy with ponatinib + blinatumomab?
Do you consider resuming Venetoclax for patients with CLL upon progression/recurrence, in whom Venetoclax/Rituximab achieved CR and Venetoclax was previously well tolerated but stopped after completing 2 years of therapy?
Is it possible to give Inotuzumab ozogamicin in the front line setting for an older patient with Ph- Pre-B-ALL?
How long do you continue ATRA during induction in high risk acute promyelocytic leukemia?
How would you treat an LGL leukemia patient who has been refractory to treatments with cyclosporine, MTX, and cyclophosphamide?
How should one approach an incidentally found T-cell gene arrangement?
What is your approach to re-challenging BTK inhibitors for a patient who has had intolerance to several different agents?
What is your current approach to maintenance therapy in FLT3-mutant AML post allogeneic HCT?
Do you prefer to use 7+3 or CPX-351 as standard induction therapy in younger patients with AML-MRC or t-AML?